SHAREHOLDER ALERT: Bronstein, Gewirtz & Grossman, LLC Announces Investigation of Ironwood Pharmaceuticals, Inc. (IRWD)

NEW YORK, April 28, 2016

This investigation concerns whether Ironwood and certain of its officers and/or directors have violated the Federal Securities Laws under the Securities Exchange Act of 1934 (the "Exchange Act"). 

On April 26, 2016 Phase Five Research published an article on Ironwood "Uncovered: fatal issues linked with Ironwood's drug, Linzess."  The Phase Five Research report said, while Ironwood has stated that the side effects of Linzess are limited to the gastrointestinal tract, the drug's "side effects are not limited to the gastrointestinal (GI) tract," and that the drug is causing "previously unknown, unreported and unlabeled severe systemic adverse events, including documented cases of rapid weight gain, renal failure, seizures and strokes."  Following this news, Ironwood dropped $0.60 per share, or 5.53%, to close at $10.25 on April 26, 2016.

If you are aware of any facts relating to this investigation, or purchased shares of Ironwood, you can assist this investigation by visiting the firm's website: http://www.bgandg.com/#!irwd/jo4yj. You can also contact Peretz Bronstein or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484 or via email info@bgandg.com.  Those who inquire by e-mail are encouraged to include their mailing address, email and telephone number.

Bronstein, Gewirtz & Grossman, LLC is a corporate litigation boutique.  Our primary expertise is the aggressive pursuit of litigation claims on behalf of our clients.  In addition to representing institutions and other investor plaintiffs in class action security litigation, the firm's expertise includes general corporate and commercial litigation, as well as securities arbitration.   Attorney advertising. Prior results do not guarantee similar outcomes.

Contact:
Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com